AngioSafe

AngioSafe is a medical device company specializing in endovascular revascularization solutions for coronary and peripheral artery disease. The company develops the Santreva-ATK platform, a wire-free intraplaque crossing and vessel preparation system designed for treating chronic total occlusions (CTOs) and severely stenotic lesions. Santreva-ATK combines three integrated mechanisms—intraplaque traversal, axial plaque cutting, lateral plaque compression, and channel formation—in a single, manually controlled, large-profile catheter system. The device is engineered to minimize complications including embolism, flow-limiting dissection, and major perforation in complex coronary and peripheral interventions. AngioSafe's technology addresses a significant clinical gap in endovascular intervention by simplifying CTO crossing procedures and reducing procedural complexity. The Santreva-ATK platform underwent clinical validation in the RESTOR-1 pivotal trial, which demonstrated successful revascularization outcomes with zero device-related major adverse events and high antegrade crossing success rates. The company positions its solution as catheterization laboratory equipment for interventional cardiologists and vascular specialists managing complex coronary artery disease. AngioSafe serves hospital cath labs and interventional centers focused on advanced coronary and peripheral revascularization procedures.